Retatrutide FDA Approval Status
Status as of 7 August 2026: not approved. Retatrutide has no FDA approval for any indication. Eli Lilly announced on 23 July 2026 that it will submit a Biologics License Application in Q1 2027 — pushed back from the Q4 2026 filing previously expected. With standard review timelines, an FDA decision would fall in late 2027 or the first half of 2028.
What retatrutide is and how it works covers the background; this page tracks only where the application stands.
Latest Update — 23 July 2026
Eli Lilly reported positive topline results from TRIUMPH-2 and TRIUMPH-3, and revised its regulatory plan.
TRIUMPH-3 enrolled 1,949 adults with severe obesity (BMI 35 or above) and established cardiovascular disease, with or without type 2 diabetes. At 80 weeks:
- 12 mg: 55.8 lbs lost, 22.6% of body weight
- 9 mg: 52.7 lbs lost, 21.6%
- Placebo: 7.7 lbs, 3.2%
- Triglycerides down 37.0%, non-HDL cholesterol down 16.5%
TRIUMPH-2, in adults with obesity and type 2 diabetes, also met its primary endpoint with improvements in both weight and HbA1c.
Two things about these numbers matter. The weight loss is lower than TRIUMPH-1’s 28.3% — expected, because both populations are harder: people with type 2 diabetes consistently lose less across this entire drug class, and TRIUMPH-3 enrolled patients with established cardiovascular disease.
The cardiovascular signal is the more consequential detail. Major adverse cardiovascular events were numerically less frequent on retatrutide, but not statistically significant — MACE-5 hazard ratio 0.82 (95% CI 0.55–1.22), MACE-3 hazard ratio 1.12 (95% CI 0.64–1.96). Event rates were low, which is what widens those intervals. Analysts described the readout as limited, and it raises questions for the dedicated TRIUMPH-Outcomes cardiovascular trial still running.
BLA, Not NDA — and Why That Distinction Matters
Most coverage of retatrutide still refers to a forthcoming New Drug Application. That is incorrect, and Lilly’s own announcement is explicit: the submission will be a Biologics License Application.
The difference is regulatory category. An NDA covers small-molecule drugs made by chemical synthesis. A BLA covers biologics — larger, more complex molecules where the manufacturing process itself is part of what is approved. Retatrutide is a 39-amino-acid peptide with a site-specific fatty acid conjugation, and it falls on the biologic side.
Practical consequences:
- Different review division and a different application pathway inside the FDA
- Manufacturing scrutiny is heavier — for a biologic, process changes can require additional regulatory work because the product is defined partly by how it is made
- Generic competition works differently — biologics face biosimilars under a separate approval route, not conventional generics
- Exclusivity terms differ — biologics receive 12 years of regulatory exclusivity in the US, against five for new chemical entities
If a page tells you retatrutide is awaiting an NDA, it has not been updated since 23 July 2026.
Revised Approval Timeline
| Stage | Timing | Status |
|---|---|---|
| TRIUMPH-4 topline | December 2025 | Complete |
| TRANSCEND-T2D-1 topline | March 2026 | Complete |
| TRIUMPH-1 topline | 21 May 2026 | Complete |
| Full data at ADA | 6 June 2026 | Complete |
| TRIUMPH-2 and TRIUMPH-3 topline | 23 July 2026 | Complete |
| BLA submission to FDA | Q1 2027 | Announced, not filed |
| FDA filing acceptance | ~60 days after submission | Projected |
| FDA decision | Late 2027 – H1 2028 | Projected |
| Commercial availability | 2028 | Projected |
Status as of 7 August 2026 — the application has not been filed
Source: Eli Lilly announcement, 23 July 2026. Timings after filing are standard FDA review periods, not company guidance. Priority review, if granted, would shorten the review stage to roughly six months.
Standard FDA review runs roughly ten months from filing acceptance. Priority review, if granted, would compress that to about six — potentially moving a decision into late 2027. Lilly has not indicated whether it will seek priority review.
Every Phase 3 Readout So Far
| Trial | Population | Result | Reported |
|---|---|---|---|
| TRIUMPH-1 | Obesity, no diabetes (n=2,339) | 28.3% at 80 wks; 30.3% at 104 wks in BMI ≥35 extension | May 2026 |
| TRIUMPH-2 | Obesity with type 2 diabetes | Met primary endpoint; weight and HbA1c improved | July 2026 |
| TRIUMPH-3 | Severe obesity + CVD (n=1,949) | 22.6% at 80 wks; MACE not significant | July 2026 |
| TRIUMPH-4 | Obesity + knee osteoarthritis | 28.7% at 68 wks | December 2025 |
| TRANSCEND-T2D-1 | Type 2 diabetes (n=537) | HbA1c −1.94; weight 16.8% at 40 wks | March 2026 |
| OSA substudy | Nested in TRIUMPH-1 | 60.6% reduction in AHI | June 2026 |
| TRIUMPH-5 | Head-to-head vs tirzepatide | Pending — completes December 2026 | Expected 2027 |
| TRIUMPH-Outcomes | Cardiovascular outcomes | Ongoing | Not announced |
The full efficacy results by trial break each of these down by dose and endpoint.
Six readouts complete, two outstanding — as of 7 August 2026
Sources: Eli Lilly announcements December 2025, March 2026, May 2026, June 2026, and 23 July 2026; ClinicalTrials.gov. Figures are highest-dose results and come from different populations and durations.
What Still Has to Happen
- Lilly files the BLA — targeted Q1 2027, not yet submitted
- FDA accepts the filing — roughly 60 days, and acceptance is not automatic
- Review — around ten months standard, six with priority review
- Advisory committee, possibly — the FDA may convene one for a first-in-class mechanism
- Outstanding trials continue — TRIUMPH-5 and TRIUMPH-Outcomes are still running; which trials are still running covers the full programme
- Decision — approval, approval with a narrowed label, or a complete response letter requesting more
- Launch — manufacturing scale-up and distribution follow approval
What Could Delay It
The cardiovascular data. TRIUMPH-3’s MACE results were not statistically significant. For a drug intended for long-term use in people who often have cardiovascular risk, the FDA may want more from TRIUMPH-Outcomes before granting a broad label.
Dysesthesia. The altered-skin-sensation signal reached 20.9% at 12 mg in TRIUMPH-4. It is distinctive to retatrutide, dose-dependent, and will shape both the label and any dosing restrictions — the dysesthesia data by dose sets out the figures.
First-in-class scrutiny. No triple agonist has ever been approved. Novel mechanisms attract closer review and are more likely to go before an advisory committee.
Manufacturing. BLA review includes the production process itself. Facility inspections and process validation are a genuine source of delay for biologics, independent of clinical data.
For trial results, safety data, dosing, cost, and comparisons with approved alternatives, browse all retatrutide coverage.
Frequently Asked Questions
Is retatrutide FDA approved?
No. As of August 2026 it has no FDA approval for any indication, and the application has not yet been filed.
When will retatrutide be FDA approved?
No date exists. Lilly plans to submit in Q1 2027; with standard review, a decision would fall in late 2027 or the first half of 2028, and availability in 2028. Until then there is no prescription route — why it cannot be prescribed until then.
Has Eli Lilly filed for FDA approval?
Not yet. On 23 July 2026 the company said it plans to submit a Biologics License Application in Q1 2027 — a shift from the Q4 2026 filing previously expected.
Why is it a BLA and not an NDA?
Retatrutide is regulated as a biologic rather than a small-molecule drug. That means a different review pathway, heavier manufacturing scrutiny, biosimilar rather than generic competition, and 12 years of regulatory exclusivity instead of five.
Why did the filing get delayed?
Lilly moved from an end-of-2026 target to Q1 2027 alongside the TRIUMPH-2 and TRIUMPH-3 readouts. The company has not given a specific reason; assembling a complete submission across multiple indications is the ordinary explanation.
Could retatrutide be rejected?
Possible. The FDA can issue a complete response letter requesting more data, or approve a narrower label than requested. The non-significant cardiovascular results and the dysesthesia signal are the most likely points of scrutiny.
Is retatrutide approved anywhere else?
No. It holds no approval from the FDA, the MHRA, the EMA, or any other regulator. The UK runs a separate track under a recognition procedure that follows the FDA’s review — see the MHRA position and UK timeline.
Sources
- Eli Lilly. “Lilly’s triple agonist, retatrutide, successful in two additional Phase 3 obesity trials.” 23 July 2026.
- Eli Lilly. TRIUMPH-1 topline results, 21 May 2026; full data ADA 86th Scientific Sessions, 6 June 2026.
- Eli Lilly. TRIUMPH-4 topline results, December 2025.
- Bajaj HS, et al. TRANSCEND-T2D-1. The Lancet. 2026.
- ClinicalTrials.gov: TRIUMPH-1 (NCT05929066), TRIUMPH-5 (NCT06662383), TRANSCEND-T2D-1 (NCT06354660).
Status verified 7 August 2026. This page is updated after each regulatory or trial announcement.